![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TEVA'S GENERIC EFFEXOR GETS FDA APPROVAL
TEVA'S GENERIC EFFEXOR GETS FDA APPROVAL
August 7, 2006
Teva Pharmaceutical Industries announced that the FDA has granted final approval for the company's generic Effexor (venlafaxine hydrochloride) tablets, 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg. Shipment of this product will begin immediately.
Teva's drug is the AB-rated generic equivalent of Wyeth's Effexor Tablets, a product indicated for the treatment of major depressive disorder. The brand product has annual sales of approximately $152 million.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct